Hypoxia, angiogenesis, and colorectal cancer

Current Colorectal Cancer Reports

Volumn 3, Issue 2, 2007, Pages 71-75

  Mizukami, Yusuke ^a   Chung, Daniel C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856848169     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-007-0003-9     Document Type: Article

References (50)

1. Chung DC: The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000, 119:854-865.
2. Suzuki H, Watkins DN, Jair KW, et al.: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004, 36:417-422.
3. Aguilera O, Fraga MF, Ballestar E, et al.: Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006, 25:4116-412.
4. Zhang X, Gaspard JP, Chung DC: Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001, 61:6050-6054.
5. Easwaran V, Lee SH, Inge L, et al.: beta-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res 2003, 63:3145-3153.
6. Jo WS, Mizukami Y, Duerr EM, et al.: Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis. Cancer Biol Ther 2005, 4:1361-1366.
7. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
8. Li J, Mizukami Y, Zhang X, et al.: Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK- 3beta. Gastroenterology 2005, 128:1907-1918.
9. Sparmann A, Bar-Sagi D: Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
10. Watnick RS, Cheng YN, Rangarajan A, et al.: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003, 3:219-231.
11. Fleming JB, Shen GL, Holloway SE, et al.: Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005, 3:413-423.
12. Ravi R, Mookerjee B, Bhujwalla ZM, et al.: Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1alpha. Genes Dev 2000, 14:34-44.
13. Teodoro JG, Parker AE, Zhu X, Green MR: p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006, 313:968-971.
14. Sasaki Y, Naishiro Y, Oshima Y, et al.: Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene 2005, 24:5131-5136.
15. Wang D, Wang H, Brown J, et al.: CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006, 203:941-951.
16. Castellone MD, Teramoto H, Williams BO, et al.: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510.
17. Baudino TA, McKay C, Pendeville-Samain H, et al.: c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002, 16:2530-2543.
18. Dews M, Homayouni A, Yu D, et al.: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006, 38:1060-1065.
19. Erler JT, Bennewith KL, Nicolau M, et al.: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
20. Koshiji M, To KK, Hammer S, et al.: HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005, 17:793-803.
21. Yao K, Gietema JA, Shida S, et al.: In vitro hypoxiaconditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Br J Cancer 2005, 93:1356-1363.
22. Bruick RK, McKnight SL: A conserved family of prolyl-4- hydroxylases that modify HIF. Science 2001, 294:1337-1340.
23. Lando D, Peet DJ, Whelan DA, et al.: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002, 295:858-861.
24. Jung CR, Hwang KS, Yoo J, et al.: E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 2006, 12:809-816.
25. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995, 92:5510-5514.
26. Koike T, Kimura N, Miyazaki K, et al.: Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A 2004, 101:8132-8137.
27. Kim JW, Tchernyshyov I, Semenza GL, Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3:177-185.
28. Papandreou I, Cairns R A, Fontana L, et al.: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006, 3:187-197.
29. Mizukami Y, Jo WS, Duerr EM, et al.: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005, 11:992-997.
30. Dang DT, Chen F, Gardner LB, et al.: Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 2006, 66:1684-1936.
31. Mizukami Y, Fujiki K, Duerr EM, et al.: Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006, 281:13957-13963.
32. Croft DR, Sahai E, Mavria G, et al.: Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res 2004, 64:8994-9001.
33. Mizukami Y, Li J, Zhang X, et al.: Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004, 64:1765-1772.
34. Ryan HE, Poloni M, McNulty W, et al.: Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000, 60:4010-4015.
35. Pore N, Liu S, Shu HK, et al.: Sp1 is involved in Aktmediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 2004, 15:4841-4853.
36. Xue Y, Bi F, Zhang X, et al.: Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation. Int J Cancer 2006, 118:2965-2972.
37. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
38. Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
39. Lyden D, Hattori K, Dias S, et al.: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201.
40. Miao HQ, Hu K, Jimenez X, et al.: Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun 2006, 345:438-445.
41. Hung K, Chung DC: New insights into the molecular pathogenesis of colorectal cancer. Drug Discov Today: Dis Mech 2006, In press.
42. Olenyuk BZ, Zhang GJ, Klco JM, et al.: Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A 2004, 101:16768-16773.
43. Kung AL, Zabludoff SD, France DS, et al.: Small molecule blockade of transcriptional coactivation of the hypoxiainducible factor pathway. Cancer Cell 2004, 6:33-43.
44. Mabjeesh NJ, Escuin D, LaVallee TM, et al.: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375.
45. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al.: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858-864.
46. Guleng B, Tateishi K, Ohta M, et al.: Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 2005, 65:5864-5871.
47. Burger JA, Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
48. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
49. Willett CG, Boucher Y, Duda DG, et al.: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
50. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.